Calculation of the resistance to CSF outflow

We read the paper by Kahlon et al with great interest. Comparative studies about the use of different diagnostic techniques to predict the response to shunting in hydrocephalus are of great value as they are likely to form a landmark for future clinical practice. Therefore, it is of paramount importance that the procedures taken for comparison are methodologically sound.

Unfortunately, the interpretation of the lumbar infusion study given by the authors raises our concern. For unknown reasons, the authors have taken into account only the end equilibrium pressure obtained during a constant rate lumbar infusion and neglected the baseline CSF pressure. The authors presumed that this pressure was the same in everybody and equal to the value resulting from the mean taken from the whole cohort (11 mm Hg).

Interpretation of the infusion study can be based only partially on the resistance to CSF outflow (Rcsf), with other parameters describing CSF dynamics like the baseline pressure, elasticity, etc., taken into account. The resistance to CSF outflow is, undoubtedly the most important parameter, about which a number of independent studies have been conducted in the past, including a quite multicentre Dutch trial.

The proper way to calculate Rcsf results from the well known Davson’s formula:

\[ \text{ICP}_{\text{baseline}} = \text{Rcsf} \times \text{Formation of CSF} + \text{Pss}; \]

where Pss is sagittal sinus pressure.

ICP reached during infusion is equal to:

\[ \text{ICP}_{\text{infusion}} = \text{Rcsf} \times \text{Formation of CSF} + \text{Infusion rate} \times \text{Pss}; \]

Subtracting the first equation from the second it can be derived:

\[ \text{ICP}_{\text{infusion}} - \text{ICP}_{\text{baseline}} = \text{Rcsf} \times \text{Infusion rate}. \]

From the last equation it seems obvious that the Rcsf must be calculated as the difference between end equilibrium CSF pressure and baseline CSF pressure, divided by the infusion rate (in this case 0.8 ml/min).

In cases when the pressure increases above 40 mm Hg during infusion, the Rcsf can be presumed to be greater than 40 minus baseline CSF pressure divided by the infusion rate.

There is still not complete agreement about which value Rcsf is normal or pathological (thresholds are ranging from 12 mm Hg/ml/min) to 19 mm Hg/ml/min), and are probably age dependent. Between 13 and 19 mm Hg/ml/min there is a "grey zone" in which patients may but they not necessarily should improve after shunting.

Is neglecting the baseline pressure likely to be a meaningful error?

Although the standard deviation of baseline CSF pressure mentioned by the authors is quite low (3 mm Hg with mean value of 11 mm Hg), this may theoretically mean that some of the patients (although less than 5%) classified as having normal pressure hydrocephalus may have baseline pressure above 17 mm Hg (that is, mean plus twice standard deviation). The “critical threshold” for CSF pressure reached during infusion study should be set for as 28, not 22 mm Hg, though.

We can recall our own material from Cambridge: in 133 adult patients presenting with clinical and radiological symptoms/signs of normal pressure hydrocephalus, constant rate lumbar infusion studies were performed. We calculated properly Rcsf, (that is, taking into account the baseline pressure) and recorded the end equilibrium pressure obtained during the test. The end equilibrium pressure, compared with the threshold calculated as in Kahlon et al (that is, resulting from the averaged baseline pressure plus 14 mm Hg/ml/min multiplied by the infusion rate), was in disagreement with the threshold value in 22 mm Hg or above in 14 mm Hg/ml/min in 23 patients. Therefore, by neglecting the baseline CSF pressure as done by Kahlon et al, we would misjudge 18% of our tests. It is not huge, but still a meaningful fraction.

M Czosnyka, Z Czosnyka, S Momjian, E Schmidt
Academic Neurosurgical Unit, Addenbrookes Hospital, Cambridge, UK
Correspondence to: Dr M Czosnyka; mc141@medschl.cam.ac.uk

References

Authors’ reply

The comment by Czosnyka and collaborators to Kahlon et al brings up a highly relevant question concerning the lumbar infusion test in patients with suspected normal pressure hydrocephalus. Namely, if calculations of the resistance to outflow of CSF (Rcsf) is a more adequate measure for predicting the outcome of a CSF shunting procedure than merely recording the steady state CSF pressure level reached during constant rate infusion as originally described by Katzman and Hussey. Czosnyka et al claim that the latter does not take the initial pressure level (that is, before infusion is started) into account. This is not totally correct. In fact in the equation for calculating Rcsf, the initial pressure level is deducted and only the effect of the fluid volume infused per unit of time is considered. This assumes that the patient’s own CSF production is similar before as well as during the infusion of artificial CSF, which may be true but is in fact not known. CSF production may well be influenced (downregulated) by longstanding hydrocephalus.

If the measured initial resting pressure is in the high range, the difference to the infusion steady state plateau pressure level will tend to decrease and if low, the difference will tend to increase. Thus, a high initial resting pressure will tend to disqualify the patient from shunt surgery and vice versa if low. These considerations stimulated us to use the uncorrected infusion steady state pressure level as was originally described to predict the outcome of shunt surgery.

Several studies have found Rcsf to be a good predictor of outcome of shunt surgery, but almost a similar number of studies have shown a less favourable predictive value (for references, see Boone et al). In two recent studies Resf and CSF outflow conductance were calculated in patients with suspected normal pressure hydrocephalus, undergoing shunt surgery based on purely clinical symptoms combined with ventricular widening. The results were partly divergent and while Malm et al confirmed that infusion conductance (reciprocal to Rcsf) had no predictive value, Boone et al. found that Rcsf could predict outcome of surgery with the best likelihood ratio at a cut off level of about 18 mm Hg/ml/min. In our study the consequence of using Rcsf calculations with cut off levels of 14 or 18 mm Hg/ml/min had been that 3% (1 of 32 patients) or 22% (7 of 32), respectively, of patients with verified improvement after shunt surgery should have been excluded from treatment.

At present we cannot see any obvious reason for not using the steady state infusion plateau level as a simple measure of CSF absorption capacity in clinical practice. From a theoretical basis we can agree to the reasoning by Czosnyka et al, but if calculation of Rcsf in clinical practice is a better predictor than merely recording the steady state plateau pressure level remains to be proved and further data are warranted. We are currently scrutinising lumbar infusion test curves to further elucidate the role of other details than only the plateau pressure for selection of patients likely to be helped by shunt operations.

B Kahlon, G Sundberg, S Rehnrona
The Department of Clinical Neuroscience, Division of Neurosurgery, University in Lund, Sweden
Correspondence to: Dr S Rehnrona; stig.rehnrona@neurokir.lu.se

References

PostScript
This book is strongly recommended to clinicians and researchers dealing with neuromuscular disorders (and to thoracic surgeons performing thymectomy).

B Lecky

Spinal cord medicine, principles and practice


Basically, this is a book about the consequences of severe spinal cord lesions, mainly traumatic injury (spinal cord injury; SCI), and the management of them. It is not a book about spinal cord diseases. So, if you are wondering about the pathogenesis of spinal interneuronal disorders or the functional integration of spinal muscular atrophies, do not look here. But if you spend a significant amount of time involved in the care of patients who are wheelchair dependent as a consequence of SCI or other spinal cord lesions, as well as coverage of more esoteric matters like the immune system and inflammatory response in persons with SCI. Major strengths are found in the multidisciplinary inputs to acute and chronic management and rehabilitation, encompassing for instance functional restoration of the upper extremity in tetraplegia, heterotopic ossification, and medical and surgical management of pressure ulcers.

With one editor-in-chief, eight associate editors, and more than 130 authors, repetition and redundancy might be predicted, and unfortunately there is lots of it. For example, no fewer than three chapters cover ejaculation in varying detail. The author of the foreword writes that the book is a magnum opus. It might be another magnum opus to go through the whole book and sort out the cross referencing, but it needs it. And there is considerable variability. Normal and abnormal micturition is dealt with in just four pages with seven references. The very next chapter, on renal insufficiency in patients with SCI, has 36 pages and 282 references.

This is an American book written for Americans. All of the contributors work in the USA or Canada. Poliomyelitis “no longer exists in the US or Canada” so gets no further mention—by the clinical chapter, but no one told the neurophysiologist, who gives polio a whole page (and deals with Kennedy’s syndrome too). There is a whole chapter of addresses of useful North American organisations, the telephone company that will install sip and puff dialling. Readers from many countries, perhaps including the UK, will be gobsmacked at the resources available to and spent on SCI patients in the US. At least some of these less blessed than America do not have gunshots as the cause of 17% of new SCI (41% in “African Americans”).

I welcome this book and trauma centres, SCI units, rehabilitation units, and neurology and neurosurgery libraries will be enriched by it, but the authors need to read each others contributions, and adjust their own correspondingly.

R W H Walker

A clinical guide to epileptic syndromes and their treatment


This book is a delightful rarity. It represents the distillation of over 30 years and 100 original publications in clinical epileptology and is a fitting culmination to Tom Panayiotopoulos’ career as an eminent clinical epilepsy specialist. Unashamedly this represents the views of a splitter rather than a lump. When it comes to the classification of syndromes, particularly those affecting children and adolescents. Although the identification of the idiopathic generalised epilepsies, such as juvenile myoclonic epilepsy, has very significant implications for treatment choice and strategy, it remains to be seen to what extent the susceptibility genes that contribute to the common epilepsies mesh with the finer details of the clinical and EEG classification of the epilepsies, and to the design of treatment strategies. In addition to clearly describing the range of epilepsy syndromes and their diagnostic features and management, there are a number of valuable diagnostic and practice tips such as how to recognise infantile spasms.

As occurs all too often, the quality of the content is not matched by the quality of the physical production of this book. This is a 400 page book that is crammed into 278 pages. Margins and borders are cut to the bone, tables and figures are squeezed into too little space and could be better presented. The shortcomings of the physical production are a considerable shortcoming of the product, so that particular aspects are easily accessible for those readers who are looking for them: tables of definitions and diagnostic tips are in red, figure legends and footnotes are in blue, and the titles of syndromes are in green.

These irritations notwithstanding, I would certainly buy this book to have available for reference when considering the correct classification of a particular patient, and for teaching purposes, and would recommend it to all colleagues who see and treat those with epilepsy, be they studying or working in secondary or tertiary referral practices.

J Duncan

Pediatric psychopharmacology: principles & practice


This is a weighty text—at nearly 800 pages and nearly 5½ lbs in the hardback edition. Far more than just a textbook of psychopharmacology, this is an introduction to and update on the biological basis of pediatric psychopharmacology as well as its clinical practice. Organised into four sections, the first covers neurobiology, developmental psychopathology, and genetics, including a well written primer on molecular genetics for those child and adolescent psychiatrists (and there are...
probably many) who have lost contact with their biomedical roots. It was, however, disappoin-
ting to see little reference to some of the exciting new imaging studies that are explor-
ing links between neurobiology and attachment status. Attachment (or affiliation as it is
too often termed) is covered, but largely in relation to autism and related disorders.

Section two collects together in one place as much information as anyone could want about
individual psychotropic agents, but also finds room for chapters on complementary medicine and
ECT—strange bedfellows in a subsection on other somatic interventions! The emphasis on placing pharmacological
treatments in the developmental context it is flagged up in the preface and is a theme that
runs through the book. A holistic and integrated approach to assessment and the management of children’s problems is
advocated clearly throughout.

In the third section, the evidence for treatment of a range of different conditions is
reviewed and explained—drug treatments are indeed not the only treatments available. The authors’ enthusiasm for the
potential value of psychopharmacology is tempered with a clear, evidence based focus, and the
chapters in this section are cautious in their interpretation of the literature and open about the absence of good ran-
donised controlled trial evidence in a number of important conditions. Helpful algorithms
summarising the evidence as well as the rationale for which treatments are recommended, alone or
in combination with drug treatments when there is evidence to support this. The MTA study showed the superiority of methyl-
phenidate over placebo in raising the performance of children with ADHD, but when treatment as usual was usually methylpheni-
date. One possible explanation was the manner in which the prescribing was carried out in that large multicentre trial, a concept that is supported here with a chapter on the prescribing of medicines.

The book concludes with a section on research and methodological considerations, including interesting chapters on changes in
prescribing trends within the US and around the world. Pediatric psychopharmacology is a rap-
idly growing field with a burgeoning literature. This book, written by clinicians who
understand the management of troubled children, brings together that literature in an
accessible format. It is up to date and well

However, it is an excellent source of information that is often not readily available, except in larger textbooks. For example, what
do you do if someone brings you a gift? What techniques should you use when interviewing children? What are the nuances of cross
cultural psychiatry? It does have its drawbacks—trainees need familiarity with
ICD-10, but information on this is lacking. There is insufficient guidance about making a
diagnosis and psychopharmacology is inade-
quate, so constant reference to a textbook is necessary.

In summary, it is a book in its 4th edition, which is definitely improving over time, but
needs some further follow up.

R Nilforoshan

The neuropsychiatry of epilepsy

Edited by Michael Trimbale and Bettina
Schmitz. Cambridge University Press,
Cambridge, 2002, £39.95, pp 337. ISBN 0-521-
81374-3

Various reviews on links between epilepsy and
psychiatry are to be found in this book. One of the aims of the editors was to enliven the
debate about these links, focusing on their
biological and psychosocial mechanisms.
The book is divided into sections (eg three chapters on cognitive aspects) and there is
an excellent cross referencing between different
chapters. The editors were right to include a section on non-epileptic attacks, although I
was disappointed that all chapters in this section were almost completely theory based.

There has been no attempt to stamp a housestyle on the various chapters. The reader
will find one chapter presenting a thorough
review and explained—drug treatments are
categorized clearly throughout.

This is not a handbook; practitioners looking for clinical guidance on how to man-
age their patients will have to carefully select
the chapters with a hands on approach. They
will find two of the chapters in the treatment
sections, written by the editors of the book, on
the behavioural consequences of anti-
convulsants and the use of psychotropics in
epilepsy particularly useful. Other chapters I
would select include those that are on the
post-ictal psychoses, dementia and epilepsy,
and subtle cognitive effects of epilepsy. All
in all a rich collection of papers and a valuable,
rather unique book.

S Fleming

Presumed curable

By Colin Gale & Robert Howard. Wrightson
Biomedical Publishing Ltd, Peterborough,

After 38 years as a clinical psychiatrist I still
find a good description of a psychiatric patient
a revelatory experience because the richness of
psychopathology will always exceed the
ability of any classification system to con-
dense it into easy categories. What has
surprised me is that this fascination does not seem to extend to many of my lay colleagues,
even though I have argued with them at sometime that the description of mental health problems is too often banal and
less interesting than the more popular equivalents such as James Herriot’s account of practising
as a vet in the Yorkshire Dales. There are several problems in writing about psychiatric
patients, two of which are often insuperable to
honest presentation; the ethical issue of confidentiality—full disclosure is seldom ap-
proved and many accounts are bowdlerised—
and the invisibility of the treatment, the
operations, that patients are perceived. At its worst this ambivalence can be expressed as
schadenfreude, the experience of pleasure at other peoples misfortunes, which clearly belittles the experience of mental illness. This
book escapes these problems, firstly by writ-
ing about patients who were admitted to the
Bethlem Hospital in the late Victorian period although their details are perhaps
obscured (certainly that rather too much is being disclo-
sed) and, secondly, avoided by a frank and objective comment to what are, in effect, the
patients’ own words.

All of them were admitted to Bethlem Hos-

tal between 1880 and 1900 and the title of the
book comes from the regulations of the hospital between 1867 and 1906, indicating that
for “non-curable” patients, two of which are often insuperable to
to be curable” were eligible for admission.

What is abundantly clear from this account is that Bethlem was not a Victorian snake pit
or workhouse. The high spot of the month was
the patient’s ball, usual concomitants of the
month were clean and unambiguous and there is no flight of ideas or circumstantiality, but the dense
writing in a small font makes reading in the
premise difficult.

The mood of the book is objectively difficult
to assess . . . but my reaction after the evalua-
tion was rather sad. The little use of diagrams,
extcept at the end of the book, and no colour
beneath the glossy exterior, makes for a gloomy atmosphere.
Neurosurgery of arteriovenous malformations and fistulas: A multimodal approach

This is an interesting text aimed solely at arteriovenous malformations but including the often forgotten arteriovenous fistulas. The authors consist of the Neurovascular Surgical Team at the Ludwig-Maximilians-Universität, Munich, in conjunction with the Chairman of Neuroradiology at the same institution and the Director of the Gamma Knife Centre in Munich. The spectrum of authors covers the multimodal approach described in the title of the book. The aim of the book is therefore to appeal to specialists of surgical, radiosurgical, and endovascular disciplines. Its aim is to highlight the evolution of treatment of arteriovenous malformations and arteriovenous fistulas since the first neurosurgical efforts to deal with excluding and excising these lesions which in the growth in what were initially admixture treatments, but are now part of a multimodal combination of treatments. I think the book does this very well. It begins by reiterating the basics with a literature review covering vasculature, epidemiology, and clinical characteristics, as well as treatment options of AVMs and fistulas of the CNS, including brain and spine.

It also considers the classification systems based on theory and the pathoanatomical relationship between morbid intervention and thus choice of treatment. It then goes on to discuss the result of the various modalities of surgery, embolisation, and radiosurgery in a detailed literature review. This is followed by an in depth analysis of the principles of surgery, endovascular, and gamma knife options. The relative risks and merits of each are compared. Finally, in true keeping with its clinical perspective, the book concludes with a number of case studies illustrating the combination of both surgical and endovascular approaches as well as exclusively endovascular, exclusively surgical, and finally major surgical cases.

I found the book was well structured and illustrated, making for an easy and informative read. It would be a very welcome addition to the library of any neurovascular unit and it would be of interest to all the disciplines involved in treating these abnormalities.

K O'Neill

HIV neurology

Do we need books anymore? I found myself asking this rather shocking question when an exceptionally keen medical student brought a series of current reviews relating to a patient we had seen in clinic together, downloaded from the internet within minutes of the clinic ending. HIV neurology provides at least one rationale for book publishing. Given the epidemiology of HIV in the UK, most neurologists will encounter HIV associated neurological problems rarely. Most of the physicians who look after patients with HIV disease are familiar with common neurological problems. Neurologists will therefore tend to find themselves either considering HIV associated disease as part of the differential diagnosis in patients whose HIV status is not known, or being asked for opinions once more straightforward HIV complications have been considered. This book seems to have been designed with this in mind and is organised to allow ease of reference.

The first section provides an overview of HIV disease with a succinct and accessible summary of the virology, with an outline of general treatment. The approach to neurological diagnosis is explored including useful concepts to help neurologists abandon Occam's razor, as they must in HIV disease. These include “time locking”, the linking of the potential complication to the stage of HIV infection; “parallel tracking”, the recognition that multiple levels of the nervous system can be involved in the same disease process to confuse the clinical presentation; and “layering”, the idea that multiple pathologies can affect the same level of the nervous system. The subsequent sections are based on the levels of the nervous system affected: predominantly non-focal complications relating to the brain; focal complications; spinal cord; peripheral nerve; and finally muscle. Each section discusses the many complications on conventional lines, epidemiology, clinical features, investigations, neuropathology, pathogenesis, and treatment. These are well referenced and throughout there is strong feeling that they have been written by someone with an extensive practical experience of the clinical problems described.

Reading the book in the usual way I did find some repetition, but this is an unfair criticism as the book is intended for reference section by section. There is also an assumption that somehow all neurological symptoms suffered by patients with HIV are in some way related to HIV and that they are immune to more conventional problems. The section on “HIV headache”, a commonly occurring throbbing headache for which no cause is found and which anecdotally responds to amitriptyline, which in other clinics seems familiar enough, perhaps best illustrates this.

These minor gripes aside I think this is a useful book, although expensive at £75. It is much more than the sum of the references within it as it brings a thoughtful integration of the clinical approach to patients with HIV neurology. For most neurologists this book will beat the internet.

G Fuller

Ageing and dementia. Current and future concepts

This contribution represents a summary of an international symposium on “ageing and dementia”, which took place in Vienna at the end of September 2001. The premise states that as a result of the aftermath of 11 September 2001, the hitherto internationally renowned invited speakers had to be reorganised within a short time. Three key issues were addressed in the meeting—factors that contribute to brain ageing, detection of mild cognitive impairment, and preventive and therapeutic methods that alter these effects. The result is 376 pages comprising 33 contributions over a range of subjects and covering a wide array of approaches from basic science to clinical matters. The authors represent a wide span of interests and countries (although I guess the first author of the publication was not necessarily always the presenting author at the symposium).

The concept of vascular dementia is summarised very well by the senior editor, and a discussion of the relevance of vascular changes and their rating on brain scans follows. Some discussion on basic process in the genesis of Alzheimer’s disease is intermingled with a contribution discussing a specific marker, followed by discussions of treatment approaches in Alzheimer’s disease and mild cognitive impairment.

The volume is something of a mixed bag, with a very useful overview written by leaders in the field, coupled with detailed experimental results. They represent, presumably, a faithful summary of the presentations at this particular symposium, but lack something of a thread with which to draw the contributions together. A degree of organisation with perhaps a brief introduction to particular subjects would have been helpful and easily achieved, with reference to the organisers’ aspirational themes. Some of the contributions are lengthy, while others are rather curt.

That being said, because of its wide approach, it will have wide appeal, and one can safely say that there is something for everybody within its covers. The editors and contributors have succeeded in producing a volume that is of relevance and a pleasure to read. One cannot underestimate the difficulties the organisers had in sustaining the impetus to continue with the meeting after the terrifying events of the 11th September, and this compendium, perhaps, is a piece of evidence to show that things can and should continue as usual.

A Burns
The nucleus of Theodor Meynert (1833–1892)

In 1664 Thomas Willis described distinct subcortical structures, then called the corpus striatum. It was believed to be the “sensorium commune” as defined by Aristotle; a central structure that received sensory modalities and initiated motor acts. By 1914, Wilson wrote that the corpus striatum “seemed to fall from its high estate and depreciate in physiological significance”. It gained importance with the discoveries that lesions of these areas would result in abnormal motor functions. The corpus striatum came to be viewed as the major “extrapyramidal motor system”.

Meynert developed new techniques and used thin serial sections stained with carmine or gold with quantitative neurohistological measurements. His major aim was to relate cortical function to varied cell types and to establish the neural association fibres (radiations of Meynert) within the brain. This preceded the work of Fritsch and Hitzig in 1870.

HISTORICAL NOTE

Meynert's powers of description were not the most lucid, and in 1896 Albert Kölliker renamed the ansa ganglion “Meynert's basal ganglion”:

“The central, nearly superficial part of the disc-like formation of Meynert's basal nucleus is found in the basal forebrain parallel to the ventral basis of the Nucleus lenticularis and underneath the Commissura anterior from its lateral entrance onwards; laterally, it reaches the Amygdaloid complex; caudally it extends towards the Tractus opticus; its oral part makes contact with Substantia perforata anterior, the medial one reaches the Tuber cinereum.”

Meynert was born in Dresden on 14 June 1833. His father was a historian, his mother an opera singer. When he was eight, the family moved to Vienna and the influence of artistic and bohemian living never quite left him.

As a student, he worked with Wedd and Rokitansky, who fostered his talents. He received his medical doctorate after an untamed student life, in 1861. On the basis of his thesis Structure and function of the brain and spinal cord and their significance in disease, he was appointed “Privatdozent” in 1865 and Director of the Prosectorium of the state psychiatric hospital in Vienna. Regarded as prophet of scientific progress, he rapidly published several pioneering discoveries. In 1873 he became professor of nervous diseases. Meynert's novel ideas drew diseases and initiated motor acts. By 1914, James Papez lists many of his main publications and biographies.

References


J M S Pearce
304 Beverley Road, Anlaby, Hull HU10 7BG, UK; email: jmspearce@freenet.co.uk

J Neurol Neurosurg Psychiatry 2003;74:1358